Sanitas
| Company type | Public limited company (before acquisition) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1922 in Kaunas, Lithuania |
| Fate | Acquired by Valeant Pharmaceuticals International, Inc. in 2011 |
| Headquarters | Kaunas , Lithuania |
Key people | Saulius Mečislovas Žemaitis (General Manager) |
| Products | Generic medicinal products including injectable solutions, tablets, capsules, ophthalmic drops, pre-filled disposable syringes |
Number of employees | 110 |
| Parent | Valeant Pharmaceuticals International, Inc. (since 2011) |
AB "Sanitas" ranks among Lithuania's most longstanding and prominent pharmaceutical enterprises, specializing in the production and distribution of generic medicinal products including injectable solutions, tablets, capsules, and ophthalmic drops. In 2011, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) completed its acquisition of the company.
History
Established in 1922 in Kaunas initially as a pharmaceutical laboratory focused on cosmetics manufacturing, Sanitas transitioned into a public limited liability company within Lithuania in 1994, subsequently listing its shares on the National Securities Exchange. As of 19 August 2011, Valeant Pharmaceuticals International controls a majority stake of 99.4%. The organization employs approximately 110 staff members, led by General Manager Saulius Mečislovas Žemaitis.
Significant developments in the company's timeline include:
- 1994: Completion of privatization and debut on the stock exchange.
- 2004: Integration of Lithuanian pharmaceutical firm AB Endokrininiai Preparatai.
- 2005: Inclusion of shares on the Main List of NASDAQ OMX Vilnius.
- 2006: Acquisition of Polish manufacturer Jelfa, enhancing the product range by over one hundred items.
- Mid-2000s: Expansion into markets such as Hungary and Bulgaria (2005), followed by entry into the Czech Republic and Slovakia (2007).
- 2006–2008: Development of a new manufacturing facility in Kaunas with funding from European Union structural programs.
- 2008: Purchase of Polish enterprise Homeofarm.
- 2011: Valeant acquired an initial 87.2% ownership for roughly €273 million; by 2013 it became the sole proprietor.
Products
Sanitas produces an assortment of pharmaceuticals including tablets, capsules, ampoules, eye drops, alongside value-added offerings such as pre-filled disposable syringes.
The company complies with European Good Manufacturing Practice (GMP) guidelines, assuring uniform quality standards and conformity with marketing authorization criteria.
The product portfolio encompasses approximately 50 distinct items. Prominent medicines distributed within Lithuania include Neocitramonas, Paracetamolis Sanitas, Neoaskofenas, Ranitidinas Sanitas, Panogastin, Latalux, Ecriten, Eufilinas Sanitas, Askorbo rūgštis Sanitas, Analginas Sanitas, Ketolgan, and Alkostop. These cover both prescription-based and over-the-counter segments.
Product categories are segmented by therapeutic focus:
- dermatology (treatment for skin conditions and dermatological cosmetic products);
- hospital pharmaceuticals (injectable medications for acute care);
- digestive system treatments;
- ophthalmology (eye health products);
- urology (medications addressing prostate and age-related ailments);
- non-prescription analgesics and anti-inflammatory agents;
- food supplements including vitamins and related nutritional products.
See also
External links
- , official corporate website